Recursion Pharmaceuticals (RXRX) Change in Receivables (2020 - 2021)

Recursion Pharmaceuticals (RXRX) posted Change in Receivables of -$16000.0 for Q3 2021, down 23.08% on a QoQ basis from -$13000.0 in Q2 2021, and down 100.05% year-over-year from $30.2 million in Q3 2020.

Recursion Pharmaceuticals (RXRX) Change in Receivables (2020 - 2021) Analysis & Trends

Recursion Pharmaceuticals' Change in Receivables history runs 2 years deep, the most recent figure standing at -$16000.0 for Q3 2021.

  • Quarterly Change in Receivables fell 100.05% year-over-year to -$16000.0 in Q3 2021, while the trailing twelve-month figure through Dec 2021 was -$114000.0 (down 2380.0% YoY) and the FY2021 annual result came in at -$114000.0, down 2380.0% from the prior year.
  • Change in Receivables was -$16000.0 for Q3 2021 at Recursion Pharmaceuticals, down from -$13000.0 in the prior quarter.
  • Across five years, Change in Receivables topped out at $30.2 million in Q3 2020 and bottomed at -$30.0 million in Q4 2020.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Change in Receivables (Qtr)
1 Oculis Holding AG 68,785.72 Bn 68,785.72 Bn - -
2 Nanobiotix 1,895.57 Bn 1,895.51 Bn - -
3 BeOne Medicines 471.35 Bn 466.56 Bn 1.35 Bn 75.30 Mn
4 NuCana 279.75 Bn 279.75 Bn - 2.84 Mn
5 Vertex Pharmaceuticals 120.24 Bn 113.00 Bn 2.59 Bn -39.80 Mn
6 Regeneron Pharmaceuticals 67.80 Bn 59.04 Bn 3.31 Bn -1.20 Mn
7 Belite Bio 62.51 Bn 62.51 Bn - -
8 Argenx Se 57.38 Bn 57.38 Bn 1.41 Bn -
9 Revolution Medicines 37.78 Bn 37.78 Bn - -
10 Recursion Pharmaceuticals 1.59 Bn 933.22 Mn -6.02 Mn -

Historic Data

Download Data
DateValue
Sep 30, 2021 -16,000.00
Sep 30, 2021 -16,000.00
Jun 30, 2021 -13,000.00
Jun 30, 2021 -13,000.00
Mar 31, 2021 -85,000.00
Mar 31, 2021 -85,000.00
Dec 31, 2020 -30.04 Mn
Dec 31, 2020 -30.04 Mn
Sep 30, 2020 30.19 Mn
Sep 30, 2020 30.19 Mn
Jun 30, 2020 -60,000.00
Jun 30, 2020 -60,000.00
Mar 31, 2020 -82,000.00
Mar 31, 2020 -82,000.00